Mass General Brigham
Health Plan

Triptodur (triptorelin)
Effective 12/1/2019

Plan	☐ MassHealth UPPL ☒Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☐ Pharmacy Benefit ☒ Medical Benefit		
Specialty Limitations	N/A		
Contact Information	**Medical and Specialty Medications** All Plans | Phone: 877-519-1908 | Fax: 855-540-3693		
	Non-Specialty Medications All Plans | Phone: 800-711-4555 | Fax: 844-403-1029		
Exceptions	N/A		

Overview
Triptorelin is an agonist analog of gonadotropin releasing hormone (GnRH) and causes suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. Triptodur is FDA indicated for treatment of central precocious puberty (CPP) in patients 2 years and older

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with Triptodur excluding when the product is obtained as samples or via manufacturer's patient assistance programs
OR
Authorization may be when the following criteria are met, and documentation has been submitted:

1. The member has a diagnosis of CPP with onset of secondary sex characteristics before age eight for females or age nine for males.
2. Member is at least 2 years of age
3. The prescriber is a pediatric endocrinologist or documentation of a consultation with a pediatric endocrinologist is provided
4. The member has had an inadequate response, adverse reaction or a contraindication to Lupron.

Limitations

1. Approvals will be granted for females up to the age of 12 and up to the age of 13 for males

References

1. Triptodur (triptorelin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; January 2019.
2. Clinical practice. Precocious puberty PubMed; N Engl J Med. 2008;358(22):2366.
3. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty; J Clin Endocrinol Metab. 2005;90(3):1371. Epub 2004 Dec 14. [PubMed]

4. Leschek EW, Flor AC, Bryant JC, et al. Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty. J Pediatr 2017; 190:229
5. Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab 2016; 29:1241
6. Lupron Depot-PED (leuprolide) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2020.
7. Bangalore Krishna K, Fuqua JS, Rogol AD, et al. Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium. Horm Res Paediatr 2019; 91:357
8. Demirbilek H, Alikasifoglu A, Gonc NE, et al. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection. Clin Endocrinol (Oxf) 2012; 76:1

Review History
09/24/18 – Reviewed
01/01/19 – Implemented
09/18/19 – Removed testing requirements, added started & stabilized requirement, and combined male and female criteria
09/16/20 – Reviewed at P&T.